跳至主要内容
临床试验/NCT00195208
NCT00195208已完成3 期

A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis.

Wyeth is now a wholly owned subsidiary of Pfizer9 个研究点 分布在 1 个国家目标入组 97 人开始时间: 2005年6月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
97
试验地点
9
主要终点
Comparison of MAO between the two formulations.

研究概览

简要总结

The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • GERD and a history of Erosive Esophagitis documented by endoscopy
  • H. pylori negative

排除标准

  • Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous vagotomy
  • Achlorhydria

结局指标

主要结局

Comparison of MAO between the two formulations.

次要结局

  • Comparison of BAO and pH parameters between the two formulations.

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验